Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma

被引:49
|
作者
Rintala, M [1 ]
Inki, P
Klemi, P
Jalkanen, M
Grénman, S
机构
[1] Univ Turku, Cent Hosp, Dept Obstet & Gynecol, FIN-20520 Turku, Finland
[2] Univ Turku, Cent Hosp, Dept Pathol, FIN-20520 Turku, Finland
[3] Turku Univ, Ctr Biotechnol, Turku, Finland
[4] Abo Akad Univ, Turku, Finland
关键词
syndecan-1; prognosis; clinical outcome; cervical carcinoma;
D O I
10.1006/gyno.1999.5595
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. The expression of syndecan-1, a cell surface heparan sulfate proteoglycan, is reduced during malignant transformation of squamous cells. Studies on squamous cell carcinoma of the head and neck have shown that syndecan-1-positive tumors are associated with longer overall and recurrence-free survival. The purpose of this study was to analyze syndecan-1 expression in invasive cervical carcinoma and to examine the association of syndecan-1 expression with prognostic factors and overall survival. Methods. The study population consisted of 124 patients treated for primary invasive carcinoma of the uterine cervix at the Turku University Central Hospital during the years 1970-1988. The material consisted of 102 (82.3%) squamous cell carcinomas, 16 (12.9%) adenocarcinomas and 1 (0.8%) adenosquamous carcinoma, 1(0.8%) small cell carcinoma, 1 (0.8%) adenoid basal carcinoma, 1 (0.8%) carcinosarcoma, and 2 (1.6%) unclassified cervical carcinomas. Syndecan-1 expression was determined on paraffin-embedded tissue blocks using a human syndecan-1-specific monoclonal antibody B-B4 and immunohistochemistry. The expression of syndecan-1 was classified according to staining intensity as well as the percentage of positively stained tumor cells. Results. Staining intensity was strong in 44 (36%) samples, while 24 (19%) specimens remained syndecan-1-negative. In 49 (40%) samples, the percentage of syndecan-1-positive cells was greater than or equal to 90%. Syndecan-1 expression, as determined by greater than or equal to 50% positively stained tumor cells, was associated with the grade of differentiation (P = 0.03) and squamous histology (P < 0.001), but was not associated with clinical stage (P = 0.16) or disease-free survival (P = 0.86). Age (P = 0.003) and clinical stage (P < 0.001) were significant prognostic factors, but syndecan-1 expression determined neither by percentage of positively stained tumor cells nor by staining intensity was associated with the outcome. Conclusions. In cervical carcinoma syndecan-1 is associated with histological differentiation grade and squamous histology, but does not predict clinical outcome. (C) 1999 Academic Press.
引用
收藏
页码:372 / 378
页数:7
相关论文
共 50 条
  • [1] Syndecan-1 in the Tumor Microenvironment
    Handra-Luca, Adriana
    TUMOR MICROENVIRONMENT: EXTRACELLULAR MATRIX COMPONENTS - PT B, 2020, 1272 : 39 - 53
  • [2] Aberrant Expression of Syndecan-1 in Cervical Cancers
    Karaszi, Katalin
    Vigh, Renata
    Mathe, Miklos
    Fullar, Alexandra
    Olah, Laszlone
    Fule, Tibor
    Papp, Zoltan
    Kovalszky, Ilona
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (04) : 2255 - 2264
  • [3] Clinical/prognostic significance of Syndecan-1 expression in invasive breast carcinoma with distant metastasis and its correlation with tumor immunity
    Wang, Huan
    Zhang, Yu
    Yang, Ziqi
    Jiang, Yong
    Wu, Lixue
    Wang, Rui
    Zhang, Zhang
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 250
  • [4] Prognostic significance of syndecan-1 expression in cervical cancers
    Kim, Yu Im
    Lee, Ahwon
    Lee, Bum Hee
    Kim, Su Young
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2011, 22 (03) : 161 - 167
  • [5] Syndecan-1 and Syndecan-4 Are Independent Indicators in Breast Carcinoma
    Lendorf, Maria E.
    Manon-Jensen, Tina
    Kronqvist, Pauliina
    Multhaupt, Hinke A. B.
    Couchman, John R.
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2011, 59 (06) : 615 - 629
  • [6] Reduction of syndecan-1 mRNA in cervical-carcinoma cells is involved with the 3′ untranslated region
    Nakanishi, K
    Yoshioka, N
    Oka, K
    Hakura, A
    INTERNATIONAL JOURNAL OF CANCER, 1999, 80 (04) : 527 - 532
  • [7] The role of syndecan-1 during endometrial carcinoma progression
    Solmaz, Ozgen Arslan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2019, 15 (06) : 1265 - 1269
  • [8] Syndecan-1 expression in renal cell carcinoma.
    Bayer-Garner, IB
    Gokden, M
    Talley, LL
    Gokden, N
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2002, 118 (04) : 621 - 622
  • [9] Loss of syndecan-1 in prostatic carcinoma: A marker of tumorigenesis
    Muhunyadzi, P
    Fan, CY
    Wilson, CS
    Givens, V
    Kohli, M
    Fink, LM
    LABORATORY INVESTIGATION, 2001, 81 (01) : 118A - 118A
  • [10] Syndecan-1 and heparanase enhance VEGF association with endothelia
    Yang, Y.
    Frith, A. E.
    Theus, A.
    MacLeod, V.
    Sanderson, R. D.
    MATRIX BIOLOGY, 2006, 25 : S60 - S60